Filters

Term Search
You can select from the dropdown list OR enter your own terms to refine the search.

Last Updated: 01/07/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 2011 publications

Biofilm Disruption Enhances Antimicrobial Therapy for Small Intestinal Bacterial Overgrowth and Intestinal Methanogen Overgrowth.

Biofilm Disruption Enhances Antimicrobial Therapy for Small Intestinal Bacterial Overgrowth and Intestinal Methanogen Overgrowth.

Journal: Cureus
Published: December 12, 2025

Quantifying treatment value under IRA: a case study of rifaximin for the treatment of overt hepatic encephalopathy using QALY and non-QALY measures.

Quantifying treatment value under IRA: a case study of rifaximin for the treatment of overt hepatic encephalopathy using QALY and non-QALY measures.

Journal: Journal of medical economics
Published: November 26, 2025

Title Not Found

Title Not Found

Journal: Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke
Published: November 26, 2025

Disease Modulating Agents in Cirrhosis.

Disease Modulating Agents in Cirrhosis.

Journal: Clinics in liver disease
Published: November 20, 2025

Reevaluating rifaximin prophylaxis in severe acute pancreatitis: A call for methodological refinement and microbiome-centric endpoints.

Reevaluating rifaximin prophylaxis in severe acute pancreatitis: A call for methodological refinement and microbiome-centric endpoints.

Journal: Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
Published: November 10, 2025

Lactulose Versus Rifaximin Monotherapy for Hepatic Encephalopathy Prevention: A Prospective Comparative Study in Patients With Cirrhosis.

Lactulose Versus Rifaximin Monotherapy for Hepatic Encephalopathy Prevention: A Prospective Comparative Study in Patients With Cirrhosis.

Journal: Cureus
Published: October 26, 2025

Current Status and Future Directions in the Pharmacologic Management of Cirrhosis.

Current Status and Future Directions in the Pharmacologic Management of Cirrhosis.

Journal: Clinics in liver disease
Published: October 18, 2025

Small Intestinal Bacterial Overgrowth in Children with Short Bowel Syndrome.

Small Intestinal Bacterial Overgrowth in Children with Short Bowel Syndrome.

Journal: Children (Basel, Switzerland)
Published: October 16, 2025

The Impact of Rifaximin on Hepatic Encephalopathy during Lenvatinib Therapy in Patients with Hepatocellular Carcinoma and Splenorenal Shunt.

The Impact of Rifaximin on Hepatic Encephalopathy during Lenvatinib Therapy in Patients with Hepatocellular Carcinoma and Splenorenal Shunt.

Journal: Internal medicine (Tokyo, Japan)
Published: October 15, 2025

Frequent high-level rifaximin resistance in Escherichia coli associated with long-term treatment of patients with liver cirrhosis: a prospective, controlled study.

Frequent high-level rifaximin resistance in Escherichia coli associated with long-term treatment of patients with liver cirrhosis: a prospective, controlled study.

Journal: Microbiology spectrum
Published: October 13, 2025

Increased risk of antimicrobial resistance in patients with cirrhosis and hepatic encephalopathy using rifaximin.

Increased risk of antimicrobial resistance in patients with cirrhosis and hepatic encephalopathy using rifaximin.

Journal: Nature communications
Published: October 07, 2025

Gut microbiome and its metabolites in liver cirrhosis: mechanisms and clinical implications.

Gut microbiome and its metabolites in liver cirrhosis: mechanisms and clinical implications.

Journal: Frontiers in cellular and infection microbiology
Published: October 02, 2025
Showing 1-12 of 2,011

Last Updated: 01/07/2026